Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Non-Current Assets: 2023-2024

Historic Other Non-Current Assets for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $4.9 million.

  • Monte Rosa Therapeutics' Other Non-Current Assets rose 0.86% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 0.86%. This contributed to the annual value of $4.9 million for FY2024, which is 6.18% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Other Non-Current Assets is $4.9 million, which was up 6.18% from $4.6 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Other Non-Current Assets ranged from a high of $4.9 million in FY2024 and a low of $4.6 million during FY2023.
  • In the last 2 years, Monte Rosa Therapeutics' Other Non-Current Assets had a median value of $4.7 million in 2023 and averaged $4.7 million.
  • Data for Monte Rosa Therapeutics' Other Non-Current Assets shows a peak YoY increased of 6.18% (in 2024) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Other Non-Current Assets (Yearly) stood at $4.6 million in 2023, then climbed by 6.18% to $4.9 million in 2024.